Compare Inovio Pharmaceuticals Inc (INO) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Impinj Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Impinj Inc trades at $136.87 (market cap $4.19B). The key difference: Impinj Inc is far larger — about 46.9× Inovio Pharmaceuticals Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PI | |
|---|---|---|
Market Cap | $89.27M | $4.19B |
Sector | Health | Technology |
52-Week High | $2.87 | $241.91 |
52-Week Low | $1.05 | $91.34 |
Enterprise Value | $60.28M | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Impinj (PI) trades at $137.72, down 0.33% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported Q1 2026 EPS of $0.14, exceeding expectations, but maintains negative net income margins and high valuation multiples. Recent insider sales and mixed news flow highlight investor caution amid specialized RFID market positioning.
PI offers growth potential in RFID technology with strong analyst buy ratings (72.7% consensus) and a $167.50 price target, but faces significant risks from profitability challenges, high debt-to-asset ratio (51.52% in 2025), and competitive pressures. The stock's outlook hinges on execution improvement and market expansion to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
